Stock Screener App

Frei -

Installieren

9.79

3.71% 0.35

Satellos Bioscience Inc (MSLE)

Überblick Nachrichten Preisverlauf Forum Prognose

Satellos Bioscience Inc Aktie (MSLE) Neueste Nachrichten

Satellos Bioscience Inc.Common Stock (MSLE) Stock Price, News, Quote & History - FinancialContent

Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update - TradingView

Satellos Bioscience Delivers Promising DMD Data With Fast Track Win - Streetwise Reports

Why Satellos Bioscience Inc. stock is skyrocketing today - Wealth Awesome

H.C. Wainwright Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Raises Target Price to $18 - Moomoo

Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data By Investing.com - Investing.com India

Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data - Investing.com South Africa

Satellos reports six-month Phase II data for SAT-3247 in Duchenne muscular dystrophy - The Pharma Letter

HC Wainwright Forecasts Strong Price Appreciation for Satellos Bioscience (NASDAQ:MSLE) Stock - MarketBeat

MSLE Maintained by HC Wainwright & Co. -- Price Target Raised to $18.00 - GuruFocus

Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 - Investing News Network

Phase II DMD Trailhead data hike Satellos’ stock - BioWorld News

Satellos Bioscience's Share Rise After SAT-3247 Shows Positive Results for Duchenne MD - Moomoo

Satellos reports positive TRAILHEAD data for DMD drug - grafa.com

Why Is Satellos Bioscience Trading Higher Today?Satellos Bioscience (NASDAQ:MSLE) - Benzinga

Satellos Bioscience Posts Encouraging Six-Month TRAILHEAD Data in Adult DMD Patients - TipRanks

[6-K] Satellos Bioscience Inc. Current Report (Foreign Issuer) | MSLE SEC FilingForm 6-K - Stock Titan

Satellos Reports Six-Month Interim TRAILHEAD Data Showing - GlobeNewswire

Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence - Sahm

Why Satellos Bioscience Inc. stock is sliding today - Wealth Awesome

If You Invested $1,000 in Satellos Bioscience Inc (MSCLF) - Stock Titan

Why Satellos Bioscience Inc. stock is rising today - Wealth Awesome

Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market - Streetwise Reports

Why Satellos Bioscience Inc. stock is plummeting today - Wealth Awesome

Satellos Bioscience Ord Shs (MSLE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Guggenheim Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $23 - Moomoo

Satellos gets FDA Fast Track for SAT-3247 - grafa.com

Satellos Bioscience up near 10% as SAT-3247 Granted FDA Fast Track Designation - marketscreener.com

Stocks in play: Satellos Bioscience Inc. - The Globe and Mail

Satellos Bioscience Shares Climb After FDA Fast Track Designation - Moomoo

Fast Track Designation for Satellos' SAT-3247 (MSLE) in Duchenne Treatment - GuruFocus

Satellos Wins FDA Fast Track Status for Duchenne Drug SAT-3247 - TipRanks

Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy - The Manila Times

FDA Fast Track boosts Satellos (NASDAQ: MSLE) SAT-3247 Duchenne program - Stock Titan

Satellos wins FDA Fast Track for Duchenne drug SAT-3247 - Stock Titan

Price to sales forward of Satellos Bioscience Inc – TSX:MSCL - TradingView

Satellos Bioscience Inc Actuals & Estimates (DUS:0IT) - TradingView

Price to earnings forward of Satellos Bioscience Inc – TSX:MSCL - TradingView

EBITDA margin % of Satellos Bioscience Inc – DUS:0IT - TradingView

Price to earnings forward of Satellos Bioscience Inc – DUS:0IT - TradingView

Enterprise value to revenue forward of Satellos Bioscience Inc – DUS:0IT - TradingView

Operating margin % of Satellos Bioscience Inc – DUS:0IT - TradingView

Satellos Bioscience Inc Statistics – DUS:0IT - TradingView

0IT Forecast — Price Target — Prediction for 2027 - TradingView

Enterprise value to revenue forward of Satellos Bioscience Inc – FWB:0IT - TradingView

Price to book forward of Satellos Bioscience Inc – FWB:0IT - TradingView

Price to earnings forward of Satellos Bioscience Inc – FWB:0IT - TradingView

Enterprise value to EBIT forward of Satellos Bioscience Inc – FWB:0IT - TradingView

Satellos Bioscience Inc Actuals & Estimates (TSX:MSCL) - TradingView

Satellos Bioscience Inc Actuals & Estimates (FWB:0IT) - TradingView

Satellos to Present Clinical Program Updates at ICNMD 2026 - Investing News Network

MSCL Forecast — Price Target — Prediction for 2027 - TradingView

Satellos to Present SAT-3247 Clinical Updates at ICNMD 2026 - TipRanks

Satellos (NASDAQ: MSLE) to present new SAT-3247 Duchenne data at ICNMD 2026 - Stock Titan

MSLE Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplinePreliminary Results - dars.gov.et

Satellos Bioscience Ord Shs (MSLE) Institutional Confidence - TradingKey

Why Satellos Bioscience Inc. stock is tanking today - Wealth Awesome

RPRX

$56.43

2.64%

INSM

$115.61

2.24%

ROIV

$35.97

2.28%

MRNA

$68.27

10.83%

ONC

$298.70

1.36%

RVMD

$186.88

2.22%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters